[A single-center, randomized controlled trial of PEG-rhG-CSF and common rhG-CSF to promote neutrophil recovery after induction chemotherapy in newly diagnosed acute myeloid leukemia].
作者： C L Zhou , Y T Liu , K Q Liu , X L Zhao , Y C Mi
DOI: 10.3760/CMA.J.ISSN.0253-2727.2019.06.009
关键词: Myeloid leukemia 、 Induction chemotherapy 、 Granulocyte 、 Gastroenterology 、 Single Center 、 Incidence (epidemiology) 、 Chemotherapy regimen 、 Randomized controlled trial 、 Medicine 、 Newly diagnosed 、 Internal medicine
摘要: Objective: To compare the time of recovery neutrophils or leukocytes by pegylated recombinant human granulocyte stimulating factor (PEG-rhG-CSF) common (rhG-CSF) in myelosuppressive phase after induction chemotherapy newly diagnosed acute myeloid leukemia (AML) patients. At same time, incidences infection and hospitalization were compared. Methods: A prospective randomized controlled trial was conducted patients with AML who met enrollment criteria from August 2014 to December 2017. The randomly divided into two groups according a 1:1 ratio: PEG-rhG-CSF group rhG-CSF group. neutrophil leukocyte recovery, rate interval compared between groups. Results: 60 enrolled: 30 There no significant differences age, regimen, pre-chemotherapy ANC, WBC, efficacy (P>0.05) . median (range) ANC WBC 19 (14-35) d (15-26) d, respectively, statistical difference (P=0.566) 90.0%and 93.3%, there (P=1.000) days 20.5 (17-49) 21 (19-43) days, (P=0.530) Conclusions: In therapy, application daily incidence time.
sci-hub.st 参考文章(23)
Joseph O. Moore, Richard K. Dodge, Philip C. Amrein, Jonathan Kolitz, Edward J. Lee, Bayard Powell, Scott Godfrey, Francisco Robert, Charles A. Schiffer, Granulocyte Colony-Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022 Blood. ,vol. 89, pp. 780- 788 ,(1997) , 10.1182/BLOOD.V89.3.780
M Fiegl, , W Hiddemann, J Braess, Use of pegylated recombinant filgrastim (Pegfilgrastim) in patients with acute myeloid leukemia: pharmacokinetics and impact on leukocyte recovery Leukemia. ,vol. 22, pp. 1284- 1285 ,(2008) , 10.1038/SJ.LEU.2405038
Jan P. Sinclair, Margaret C. Croxson, Stephen M Thomas, Lochie R. Teague, David C. Mauger, Chronic parvovirus B19 meningitis in a child with acute lymphocytic leukemia. Pediatric Infectious Disease Journal. ,vol. 18, pp. 395- 396 ,(1999) , 10.1097/00006454-199904000-00024
Jorge Sierra, Jeffrey Szer, Jeannine Kassis, Richard Herrmann, Mario Lazzarino, Xavier Thomas, Stephen J Noga, Nigel Baker, Roger Dansey, Alberto Bosi, A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial BMC Cancer. ,vol. 8, pp. 195- 195 ,(2008) , 10.1186/1471-2407-8-195
Simona Bassi, Cristina Rabascio, Luca Nassi, Sara Steffanoni, Aleksandra Babic, Paola Bertazzoni, Federica Gigli, Pierluigi Antoniotti, Laura Orlando, Simona Sammassimo, Jessica Quarna, Mara Negri, Giovanni Martinelli, A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy Transfusion and Apheresis Science. ,vol. 43, pp. 321- 326 ,(2010) , 10.1016/J.TRANSCI.2010.10.001
Barbara Pro, Luis Fayad, Peter Mclaughlin, Jorge Romaguera, Fredrick B. Hagemeister, Maria A. Rodriguez, Andre Goy, Evelyn Loyer, Anas Younes, Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma. ,vol. 47, pp. 481- 485 ,(2006) , 10.1080/10428190500305802
Olfa Derbel, Giovanna Cannas, Quoc-Hung Le, Mohamed Elhamri, Youcef Chelghoum, Emmanuelle Nicolas-Virelizier, Franck Nicolini, Jacques Troncy, Fiorenza Barraco, Mauricette Michallet, Xavier Thomas, A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule. Hematology. ,vol. 15, pp. 125- 131 ,(2010) , 10.1179/102453309X12583347113654
Jan Braess, Karsten Spiekermann, Peter Staib, Andreas Grüneisen, Bernhard Wörmann, Wolf-Dieter Ludwig, Hubert Serve, Albrecht Reichle, Rudolf Peceny, Daniel Oruzio, Christoph Schmid, Xaver Schiel, Marcus Hentrich, Christina Sauerland, Michael Unterhalt, Michael Fiegl, Wolfgang Kern, Christian Buske, Stefan Bohlander, Achim Heinecke, Herrad Baurmann, Dietrich W. Beelen, Wolfgang E. Berdel, Thomas Büchner, Wolfgang Hiddemann, Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood. ,vol. 113, pp. 3903- 3910 ,(2009) , 10.1182/BLOOD-2008-07-162842
Ulrich J. M. Mey, Anna Maier, Ingo G. H. Schmidt-Wolf, Carsten Ziske, Helmut Forstbauer, Gamal-Andre Banat, Michael Reber, John W. Strehl, Marcus Gorschlueter, Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Supportive Care in Cancer. ,vol. 15, pp. 877- 884 ,(2007) , 10.1007/S00520-006-0201-Z
Grace Kam, Richard Yiu, Yvonne Loh, Ai Leen Ang, Ling Ling Yueh, Yeow Tee Goh, Gee Chuan Wong, Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy Supportive Care in Cancer. ,vol. 23, pp. 643- 649 ,(2015) , 10.1007/S00520-014-2417-7